Poolbeg Pharma PLC (LON:POLB – Get Free Report) shares shot up 5.2% during mid-day trading on Wednesday . The company traded as high as GBX 8.10 ($0.11) and last traded at GBX 8.10 ($0.11). 475,472 shares were traded during trading, a decline of 73% from the average session volume of 1,772,456 shares. The stock had previously closed at GBX 7.70 ($0.10).
Poolbeg Pharma Price Performance
The stock has a market capitalization of £39 million, a P/E ratio of -810.00 and a beta of 2.11. The stock’s fifty day moving average price is GBX 9.74 and its 200 day moving average price is GBX 11.65.
Poolbeg Pharma Company Profile
Poolbeg Pharma plc operates as a biopharmaceutical company in the United Kingdom. It develops POLB 001, a p38 MAP Kinase inhibitor for the treatment of severe influenza; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis.
Further Reading
- Five stocks we like better than Poolbeg Pharma
- The 3 Best Fintech Stocks to Buy Now
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- What is the NASDAQ Stock Exchange?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- Why is the Ex-Dividend Date Significant to Investors?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Poolbeg Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poolbeg Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
